Molnupiravir Impurity 17 - Request Quote
Molnupiravir Impurity 17
| SZ CAT No: | SZ-M094024 |
| CAS No | NA |
| Mol.F. | C16H23N3O7 |
| Mol.Wt. | 369.4 |
| Inv. Status | Synthesis on demand |
Chemical Name :
Shipping Temperature :
HSN Code :
Country of Origin :
Smiles :
Usage Note:
Molnupiravir Impurity 17 is chemically ((3aS,4S,6S,6aS)-6-(4-(hydroxyamino)-2-oxopyrimidin-1(2H)-yl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methyl isobutyrate. Molnupiravir Impurity 17 is supplied with detailed characterization data compliant with regulatory guideline. Molnupiravir Impurity 17 can be used for the analytical method development, method validation (AMV), Quality Controlled (QC) application for Abbreviated New Drug Application (ANDA) or during commercial production of Molnupiravir.
The product can be used as reference standards and further traceability against pharmacopeial standards (USP or EP) can be provided based on feasibility. SynZeal products are for analytical purpose only and not for human use.
Applications & Regulatory Use Cases
buy high quality Molnupiravir Impurity 17
Purchase Molnupiravir Impurity 17
Molnupiravir Impurity 17 suppliers
Molnupiravir Impurity 17 manufacturers
Molnupiravir Impurity 17 price
Order Molnupiravir Impurity 17
Enquire Molnupiravir Impurity 17
Molnupiravir Impurity 17 cost
Molnupiravir Impurity 17 Supplier
Molnupiravir Impurity 17 Distributor
Molnupiravir Impurity 17 for Method Validation
Molnupiravir Reference Standard
Molnupiravir Impurity 17 for ANDA Filing
Molnupiravir Impurity 17 for Forced Degradation Studies
Molnupiravir Impurity 17 Identification Standards
Molnupiravir Impurity 17 for DMF Filing
Related Products
Disclaimer
SynZeal product information given on this website is as per the existing understanding while publishing the details on website. The customer is responsible for assessing the accuracy of the information at the time of actual purchase.
SynZeal will update these details as per new developments or findings in product specifications without further notice.


